This newsletter presents you the following key sessions:
1. Podcast with Dr. Laurence Buisseret about first-line chemoimmunotherapy with durvalumab, paclitaxel,
and carboplatin with or without the anti-CD73 antibody oleclumab to treat advanced or metastatic
triple-negative breast cancer
2. Tumour-infiltrating lymphocytes improve progression-free survival in previously treated advanced
melanoma patients
3. Maintenance olaparib plus bevacizumab after first-line chemotherapy as a standard of care for
advanced ovarian cancer
4. How air pollution may trigger lung cancer in never-smokers: towards molecular cancer prevention?
5. Notch pathway inhibitor nirogacestat improves outcomes in patients with desmoid tumours
